Periodic Reporting for period 1 - RASMAC (Regulatory Approved Software for Mutation Analysis in Cancer)
Okres sprawozdawczy: 2019-08-01 do 2020-01-31
The overall objective of this project was to develop and optimize a business plan that will guide the development and commercialization of RASMAC - the first CE/IVD- certified commercial software as a medical device (SaMD) for cancer precision diagnostics.
The feasibility study has confirmed a significant business opportunity within the European and global precision diagnostic oncology market.
We strive to develop our product further and to harness the full potential of a medical device software enabling data-driven precision diagnostic oncology. Cancer is a serious global health problem and Oncodia is convinced its innovative medical device will have a significant impact on the cancer burden in Europe and worldwide.